What is the price target for HYL stock?
7 analysts have analysed HYL.BR and the average price target is 13.84 EUR. This implies a price increase of 158.17% is expected in the next year compared to the current price of 5.36.
HYLORIS PHARMACEUTICALS SA (HYL.BR) Forecast, Price Target & Analyst Ratings
EBR:HYL • BE0974363955
Current stock price
5.36 EUR
+0.08 (+1.52%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HYLORIS PHARMACEUTICALS SA (HYL.BR).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
€13.84
Upside
+ 158.17%
From current price of €5.36 to mean target of €13.84, Based on 7 analyst forecasts
Low
€6.06
Median
€14.59
High
€21.42
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for HYL.BR. The average price target is 13.84 EUR. This implies a price increase of 158.17% is expected in the next year compared to the current price of 5.36.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
HYL.BR was analyzed by 7 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about HYL.BR.
In the previous month the buy percentage consensus was at a similar level.
HYL.BR was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-12-22 | KBC SECURITIES | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.087M 131.89% | 8.458M 305.27% | 7.207M -14.79% | 35.931M 398.56% | 76.785M 113.70% | 156.9M 104.34% | |
| EBITDA YoY % growth | -15.497M -37.00% | -5.721M 63.08% | -6.79M -18.69% | 7.07M 204.12% | 35.779M 406.07% | 117.06M 227.18% | |
| EBIT YoY % growth | -15.846M -37.70% | -6.369M 59.81% | -7.709M -21.04% | 7.979M 203.50% | 36.941M 362.98% | N/A | |
| Operating Margin | -759.27% | -75.30% | -106.97% | 22.21% | 48.11% | N/A | |
| EPS YoY % growth | N/A -26.67% | N/A 2.34% | N/A 38.32% | -0.22 36.89% | 0.52 335.38% | 3.23 527.45% |
All data in EUR
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
124.54%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
110.52%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
198.25%
EBIT Next 5 Year
N/A
HYLORIS PHARMACEUTICALS SA / HYL.BR Forecast FAQ
What is the number of analysts for HYL stock?
The number of analysts covering HYLORIS PHARMACEUTICALS SA (HYL.BR) is 7.